This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris
Ticker(s): AZN, ALXNWho's the expert?
Institution: Pediatric Subspecialty Foundation
- Pediatric hematologist with a focus on coagulation and thrombotic microangiopathy who treats 2 patients with PNH
- Research focus in prevention of blood clots in children, utilization and cost-effectiveness of thrombophilia testing, coagulopathy of trauma, and health economics of bleeding and clotting disorders.
- Medical school at Michigan State University/College of Human Medicine; Pediatric residency and fellowship training in pediatric hematology-oncology at Riley Hospital for Children/University of Indiana.
Interview GoalTo discuss the standard of care in treating PNH and discuss the relevance of Danicopan in this space
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
